Recent therapeutic innovations are significantly changing the management of young children with severe haemophilia. A team from the University Hospital of Nice (06) introduced emicizumab, the first subcutaneous non-replacement therapy. Integrated into the multi-professional management of children and their families, this innovative therapeutic option has shown encouraging initial results. Experience sharing.
Keywords: emicizumab; haemophilia; hémophilie; innovation thérapeutique; management; prise en charge; quality of life; qualité de vie; safety; sécurité; therapeutic innovation.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.